Opinion|Videos|February 5, 2025
Treatment and Co-Management of mCRPC Patients with Aggressive Disease
Author(s)Jose De La Cerda III, MD, MPH
This video segment explores treatment approaches for PSMA-positive mCRPC patients, algorithms for monitoring liver dysfunction in advanced CRPC, and exciting advancements in mCRPC treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- If the patient is positive for prostate-specific membrane antigen (PSMA), how would you treat the patient?
- What is your algorithm for monitoring patients with liver dysfunction and advanced CRPC?
- What advances in treatment of mCRPC are you most excited about?
Advertisement
Related Content
Advertisement
Advertisement
Trending on Urology Times
1
Alternative BCG strains may help address ongoing supply challenges in NMIBC
2
Doublet or triplet? Urologists weighs in on mCSPC options
3
Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA
4
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
5